Global Analgesics Market Report 2020: Market to Reach $78.1 Billion - Forecast to 2030
16 févr. 2021 04h28 HE
|
Research and Markets
Dublin, Feb. 16, 2021 (GLOBE NEWSWIRE) -- The "Analgesics Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering. The global...
Paediatric Consumer Health in Germany to 2024 - Good Pace of Growth to Continue
18 janv. 2021 09h43 HE
|
Research and Markets
Dublin, Jan. 18, 2021 (GLOBE NEWSWIRE) -- The "Paediatric Consumer Health in Germany" report has been added to ResearchAndMarkets.com's offering. Similar to its impact on adult analgesics and...
PledPharma presenterar resultat från studie på läkemedelskandidaten Aladote® för paracetamolförgiftning på global toxikologikonferens
13 déc. 2018 02h00 HE
|
PledPharma AB
Stockholm, 13 december 2018. PledPharma AB (publ) meddelar att bolagets Aladote® fas Ib/IIa studieresultat har accepterats för presentation på den globala toxikologikonferensen ”58th Annual Meeting of...
PledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conference
13 déc. 2018 02h00 HE
|
PledPharma AB
Stockholm, December 13, 2018. PledPharma AB (publ) announces that the company's Aladote® Phase Ib/IIa study results has been accepted for a poster presentation during the “58th Annual Meeting of the...
PledPharma redovisar positiva slutresultat från klinisk proof of principle-studie av Aladote®
24 sept. 2018 02h30 HE
|
PledPharma AB
Stockholm, 24 september 2018. PledPharma AB (publ) meddelar idag att proof of principle-studien av Aladote® framgångsrikt har slutförts, och att studiens primära syfte – att dokumentera...
Pledpharma announces positive results from the Aladote® proof of principle study
24 sept. 2018 02h30 HE
|
PledPharma AB
Stockholm, September 24, 2018. Today PledPharma (publ) announces that the Aladote® proof of principle study in patients with paracetamol overdose at risk of liver damage has successfully met the...
Global Para Nitrochlorobenzene (PNCB) Market to witness a CAGR of 3.3% during 2018-2024
27 août 2018 06h01 HE
|
Energias Market Research
NEW YORK, Aug. 27, 2018 (GLOBE NEWSWIRE) -- The global para nitrochlorobenzene (PNCB) market was valued at USD 96.0 million in 2017 and is likely to expand to USD 120.4 million by 2024, witnessing a...
Aladote® uppvisar god säkerhetsprofil i den första kliniska studien – PledPharma planerar ansöka om särläkemedelsstatus i USA
25 juin 2018 02h30 HE
|
PledPharma AB
PledPharma AB (publ) meddelar idag resultaten från en oberoende utvärdering av data från den kliniska proof-of-principle-studien (fas 1b/2a) av Aladote®. Utvärderingen, som utförts av studiens Data...
Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US
25 juin 2018 02h30 HE
|
PledPharma AB
Today PledPharma (publ) announces that the company has received a positive conclusion of the safety evaluation from the Data Safety Monitoring Board for the Aladote proof of principle study in...
Can Common Pain Relievers Do More Harm Than Good?
20 sept. 2011 11h26 HE
|
BioResource, Inc.
SAN FRANCISCO, CA--(Marketwire - Sep 20, 2011) - When it comes to relieving the common headache or body aches, it seems as if the cure may be worse for you than the pain it's supposed to relieve.
...